Literature DB >> 26433062

Preventing Thrombosis to Improve Outcomes in Heart Failure Patients.

Eduard Shantsila1, Gregory Y H Lip2.   

Abstract

Heart failure (HF) is associated with an increased risk of thrombotic events, particularly if this condition is accompanied by atrial fibrillation (AF). Many HF patients have background coronary artery disease (CAD) making them prone to coronary thrombosis resulting in myocardial infarction or sudden death. Oral anticoagulation is essential in the vast majority of HF patients with AF with non-vitamin K based anticoagulants being a suitable alternative to warfarin. In contrast, aspirin alone does not provide adequate stroke prevention in such patients. In HF without AF, oral anticoagulation should not be routinely used, and antiplatelet agents should be prescribed in patients with background CAD. This review provides an overview of prothrombotic factors and antithrombotic management of patients with HF.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; Heart failure; Oral anticoagulants; Thrombosis

Mesh:

Substances:

Year:  2015        PMID: 26433062     DOI: 10.1016/j.pcad.2015.09.005

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  3 in total

Review 1.  Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm.

Authors:  Eduard Shantsila; Gregory Yh Lip
Journal:  Cochrane Database Syst Rev       Date:  2016-09-15

Review 2.  Should atrial fibrillation patients with hypertension as an additional risk factor of the CHA2DS2-VASc score receive oral anticoagulation?

Authors:  Juan Wang; Da-Peng Zhang; Hong-Bin Liu; Jiu-Chang Zhong; Xin-Chun Yang
Journal:  J Geriatr Cardiol       Date:  2018-03       Impact factor: 3.327

3.  Pharmaceutical Care Increases Time in Therapeutic Range of Patients With Poor Quality of Anticoagulation With Warfarin.

Authors:  Leiliane Rodrigues Marcatto; Luciana Sacilotto; Letícia Camargo Tavares; Mirella Facin; Natália Olivetti; Celia Maria Cassaro Strunz; Francisco Carlos Costa Darrieux; Maurício Ibrahim Scanavacca; Jose Eduardo Krieger; Alexandre Costa Pereira; Paulo Caleb Junior Lima Santos
Journal:  Front Pharmacol       Date:  2018-09-21       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.